EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trends in Primary- and Metastasis-Directed Radiotherapy Uptake and Survival in Metastatic Prostate Cancer

James O Suggitt iD, Tej A Patel iD, Miranda B Lam iD, Irini Yacoub, Puneeth Iyengar, Sean M McBride, Himanshu Nagar iD, Paul L Nguyen, Daniel Gorovets, Jonathan E Leeman, Edward Christopher Dee iD

Journal of Clinical Medicine · 15.04.2026 · 15 (8) · 3010

DOI: 10.3390/jcm15083010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.04.2026. Verfasst von James O Suggitt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Grossman School of Medicine, New York University, New York, NY 10016, USA. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: This study investigates trends in radiotherapy utilization in men with metastatic prostate cancer, particularly in response to pivotal trials like STAMPEDE and STOMP, which demonstrated survival benefits for primary- and metastasis-directed radiotherapy.

Methods

Using data from the National Cancer Database, the study analyses changes in treatment patterns post-2018.

Results

Prior to 2018, 13.3% and 10.9% of patients with metastatic prostate cancer received primary- and metastasis-directed radiotherapy, respectively; these proportions increased modestly to 14.0% and 12.1% following 2018 (χ2 p < 0.0001 for both). Significant differences in comorbidity prevalence were observed both temporally (CDCI mean 0.35 prior to 2018 vs. 0.46 post-2018, p < 0.0001), and between those treated with primary- and metastasis-directed radiotherapy (CDCI mean 0.34 in primary-directed vs. 0.45 in metastasis-directed, p < 0.0001). Primary-directed radiotherapy was associated with improved overall survival across all years (HR 0.87, p < 0.0001), but it was associated with lower survival when restricted to post-2018 diagnoses (HR 1.24, p < 0.0001). Metastasis-directed radiotherapy was not significantly associated with overall survival benefit regardless of era (M1a: HR 1.58, p = 0.27; M1b: HR 0.97, p = 0.29), though non-receipt after 2018 was associated with markedly increased mortality (HR 18.54, p < 0.0001).

Conclusions

Pivotal clinical trials temporally align with shifts in radiotherapy practices among M1 disease subgroups. The potential survival benefit of radiotherapy to the primary site and to metastases among patients with metastatic disease merits further investigation in the real-world setting. Further work may highlight differences in patient populations or overall efficacy of radiotherapy in these populations.

Schlagwörter

Stichwörter der Autor:innen

genitourinary cancermetastasis-directed radiotherapymetastatic prostate cancerprimary-directed radiotherapyradiotherapyradiotherapy uptake trends

Autor:innen und Institutionen

  • Department of Radiation Oncology, Grossman School of Medicine, New York University, New York, NY 10016, USA.
  • Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
  • Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA 02215, USA.
  • Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • New York Proton Center, New York, NY 10035, USA.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

ORCID-Profile: James O Suggitt, Tej A Patel, Miranda B Lam, Himanshu Nagar, Edward Christopher Dee

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Suggitt, J. O., Patel, T. A., Lam, M. B., Yacoub, I., Iyengar, P., McBride, S. M., Nagar, H., Nguyen, P. L., Gorovets, D., Leeman, J. E., & Dee, E. C. (2026). Trends in Primary- and Metastasis-Directed Radiotherapy Uptake and Survival in Metastatic Prostate Cancer. Journal of Clinical Medicine, 15(8), 3010. https://doi.org/10.3390/jcm15083010

Vancouver

Suggitt JO, Patel TA, Lam MB, Yacoub I, Iyengar P, McBride SM, et al. Trends in Primary- and Metastasis-Directed Radiotherapy Uptake and Survival in Metastatic Prostate Cancer. Journal of Clinical Medicine. 2026;15(8):3010. doi:10.3390/jcm15083010

BibTeX
@article{Suggitt2026,
  author = {Suggitt, James O and Patel, Tej A and Lam, Miranda B and Yacoub, Irini and Iyengar, Puneeth and McBride, Sean M and Nagar, Himanshu and Nguyen, Paul L and Gorovets, Daniel and Leeman, Jonathan E and Dee, Edward Christopher},
  title = {Trends in Primary- and Metastasis-Directed Radiotherapy Uptake and Survival in Metastatic Prostate Cancer},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {8},
  pages = {3010},
  doi = {10.3390/jcm15083010}
}
Kostenlos starten →